紫杉醇在宫颈癌术前新辅助化疗中的应用  

Application of paclitaxel in neoadjuvant chemotherapy in patients with cervical cancer

作　　者：潘玫[1] 李隆玉[1] 罗兵[1] 舒宽勇[1] 李汉萍[1] 邓克华[1] 

机构地区：[1]江西省妇幼保健院肿瘤科,江西南昌330006

出　　处：《现代肿瘤医学》2009年第4期711-712,共2页Journal of Modern Oncology

摘　　要：目的:研究紫杉醇在局部晚期宫颈癌术前新辅助化疗中的作用。方法:应用紫杉醇联合铂类经静脉或静脉+腹腔化疗,对局部晚期宫颈癌Ib2-IIIb术前予新辅助化疗,观察50例患者化疗前后局部肿瘤体积变化、手术切除率、盆腔淋巴结转移、脉管癌栓、病灶局部化疗反应。结果:紫杉醇联合化疗(PT)作为术前新辅助化疗,肿瘤体积缩小总有效率84%,CR34%,手术切除率84%。结论:PT方案联合化疗在局部晚期宫颈癌术前新辅助化疗方面较传统治疗方案有较明显优势。Objective：To investigate the effect of paclitaxel in neoadjuvant chemotherapy in patients with locally advanced cervical cancer. Methods：A total of 50 patients dignosed by pathology with locally advanced cervical cancer in stage Ⅰb2 -Ⅲb were treated with paclitaxel combined cisplatin by intravenous chemotherapy or combined intraperitoneal and intravenous chemotherapy,to observe the change of tumor, resectable rate, pelvic lymph node metastasis, lymph vascular space involvement, chemo -reaction of local lesion. Results：The overall response rate was 84% , complete recovery （CR） rate was 34% ,resectable rate was 84%. Conclusion：There is an obvious predominance for the chemotherapy with paclitaxel combined cisplatin in neoadjuvant chemotherapy in patients with locally advanced cervical cancer before operation.

关 键 词：紫杉醇 局部晚期宫颈癌 术前新辅助化疗 

分 类 号：R737.33[医药卫生—肿瘤]